Centiva Capital, LP Arcutis Biotherapeutics, Inc. Transaction History

Centiva Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$1.84 - $4.82 $347,789 - $911,057	-189,016 Reduced 90.01%	20,984 $67,000
Q3 2023 Nov 14, 2023	BUY	$5.31 - $10.98 $637,200 - $1.32 Million	120,000 Added 133.33%	210,000 $1.12 Million
Q2 2023 Aug 14, 2023	SELL	$7.51 - $15.0 $826,100 - $1.65 Million	-110,000 Reduced 55.0%	90,000 $857,000
Q1 2023 May 15, 2023	BUY	$10.23 - $17.14 $2.05 Million - $3.43 Million	200,000 New	200,000 $2.2 Million
Q3 2022 Nov 14, 2022	BUY	$17.85 - $26.95 $892,500 - $1.35 Million	50,000 New	50,000 $956,000
Q2 2022 Aug 15, 2022	SELL	$16.33 - $22.2 $420,154 - $571,183	-25,729 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$14.38 - $22.79 $369,983 - $586,363	25,729 New	25,729 $496,000

197

129M

738K

82K

Ticker ARQT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,187,500
Market Cap $763M
Description
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...

Get notified when there are updates to the investment portfolio of Centiva Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Centiva Capital, LP with notifications on news.